Drugs News and Research

RSS

Standard naloxone doses may not reverse newer synthetic opioid overdoses

A new study exposes challenges in reversing opioid overdoses with naloxone when potent synthetic drugs like fentanyl and sufentanil are involved, according to a study in the May 2026 issue of Anesthesiology, the peer-reviewed medical journal of the American Society of Anesthesiologists (ASA).

13 Apr 2026

Natural peptide PEPITEM shows promise in reducing arthritic joint swelling

Scientists investigating the naturally occurring immunopeptide PEPITEM have shown reductions in arthritic joint swelling to a degree comparable to the current standard of care, and reduce the inflammatory changes that cause joint damage.

13 Apr 2026

Higher mortality risk in IBS patients using antidepressants

Research indicates that antidepressant use in IBS is linked to a 35% higher risk of all-cause mortality, highlighting safety issues with long-term treatment.

13 Apr 2026

Genetic variants may reduce effectiveness of popular diabetes drugs

More than a quarter of people with Type 2 diabetes take GLP-1 receptor agonists, but the popular diabetes drugs might not work as well for people who have certain genetic variants, according to a new study by Stanford Medicine scientists and their collaborators.

12 Apr 2026

New target CD43 may improve leukemia immunotherapy outcomes

Macrophages, much like Alice of "Alice in Wonderland," recognize and consume tumor cells that display "eat me" surface markers.

11 Apr 2026

Study reveals why immunotherapy fails in pancreatic cancer

Researchers at Oregon Health & Science University have uncovered a key reason why immunotherapy has largely failed in pancreatic cancer - and identified a promising strategy to overcome that resistance.

11 Apr 2026

Damon Runyon supports young scientists driving cancer research innovation

The Damon Runyon Cancer Research Foundation has named 13 new Damon Runyon Fellows, exceptional postdoctoral scientists conducting basic and translational cancer research in the laboratories of leading senior investigators.

11 Apr 2026

Alligator Bioscience provides an update on mitazalimab

Alligator Bioscience, a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today provided a brief update regarding mitazalimab.

From Alligator Bioscience 11 Apr 2026

Brain pathways combine memory and reward to guide behavior

New research from the University of Maryland, Baltimore County (UMBC) reveals how two different parts of the brain's memory center team up in a key reward region to help mice-and likely humans-combine memories of places and contexts with the drive to pursue rewards.

10 Apr 2026

EV-RNAs show promise for IBD diagnosis and treatment

A research team led by Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, has published a comprehensive review in ExRNA that sorts out the diverse roles of extracellular vesicle-associated RNAs (EV-RNAs) in the development and progression of inflammatory bowel disease (IBD).

10 Apr 2026

Insilico Medicine launches Pharma AI Spring Kickoff 2026 webinar

As the AI era becomes increasingly shaped by foundation models, the pharmaceutical industry is entering a new phase of opportunity for discovery, design, and decision-making driven by AI for science.

10 Apr 2026

Nanomedicine offers targeted solutions for breast cancer treatment

Breast cancer (BCA) is one of the most common cancers worldwide, with high mortality and morbidity in women.

10 Apr 2026

AI analyzes Reddit posts to find underreported GLP-1 side effects

By using AI to analyze more than 400,000 Reddit posts, Penn researchers have identified patient-reported symptoms associated with GLP-1s, the popular weight-loss and diabetes drugs semaglutide and tirzepatide, that may not be fully captured in clinical trials or regulatory documents.

10 Apr 2026

Extracellular vesicles from menstrual blood cells show potential to stimulate cartilage repair

New research by an interdisciplinary team in Lithuania has revealed a promising and unconventional approach to cartilage regeneration.

10 Apr 2026

GLP-1 and dual GLP-1 / GIP drugs help lose body fat while preserving lean mass

New research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that patients using GLP-1 or combined GLP-1 / GIP receptor agonist therapy for weight loss experienced minimal lean muscle mass loss as they lost weight across 6 months of treatment.

10 Apr 2026

Sylvester Comprehensive Cancer Center opens new trial for neuroendocrine tumors

A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

10 Apr 2026

When omega-3 may help mental health and when they may not

Investigating omega-3 fatty acids, this review highlights their impact on mental health, inflammation, and the potential for therapeutic use in disorders.

10 Apr 2026

For many patients leaving the ICU, the struggle has only just begun

The accident happened in Pittsburgh on Nov. 16. Joseph Masterson, a lawyer who was just days from retiring at age 63, suffered cardiac arrest while driving, plowed into a guardrail, and lost consciousness.

10 Apr 2026

Study finds nutritional risks in users of GLP-1 drugs

Adults with overweight or obesity taking the new generation of weight loss drugs semaglutide and tirzepatide tend to eat significantly less, leaving them vulnerable to nutritional deficiencies, according to one of the first real-world studies to examine dietary behavior in people using glucagon-like peptide-1 receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) dual agonists RAs (collectively referred to as GLP-1 RAs) with the help of an AI-powered nutritional tracking app.

9 Apr 2026

FTC drug divestiture policy may reduce competition, study finds

Last month, Novartis completed its $11 billion acquisition of Avidity Biosciences-the latest in a string of major pharmaceutical mergers including Merck's acquisition of Verona Pharma and GSK's acquisition of RAPT Therapeutics.

9 Apr 2026